Latest On Autolus Therapeutics plc (AUTL):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-07 15:51 EST | News | Autolus Therapeutics plc 2023 Q1 - Results - Earnings Call Presentation | N/A |  |
| 2023-05-07 15:51 EST | News | Autolus Therapeutics plc (AUTL) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-04 08:04 EST | News | Autolus Therapeutics GAAP EPS of -$0.23 beats by $0.04 | N/A | |
| 2023-03-14 15:28 EST | News | Autolus Therapeutics finance chief steps down | N/A | |
| 2023-03-07 14:48 EST | News | Autolus Therapeutics GAAP EPS of -$1.57 beats by $0.06, revenue of $6.36M misses by $4.47M | N/A | |
| 2023-03-07 14:48 EST | News | Autolus Therapeutics (AUTL) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-07 00:03 EST | News | Autolus Therapeutics FY 2022 Earnings Preview | N/A | |
| 2023-02-15 06:45 EST | News | Autolus: Investment Case Further Entrenched With Latest Interim FELIX Data | N/A | |
| 2023-02-14 18:07 EST | News | Autolus Therapeutics: The Story Has Improved | N/A | |
| 2022-12-09 12:50 EST | News | Autolus Therapeutics stock slide on pricing $150.0M ADS offering | N/A | |
| 2022-12-08 20:05 EST | News | Autolus says mid-stage trial of CAR-T therapy for type of leukemia met main goal | N/A | |
| 2022-12-08 20:05 EST | News | Autolus Therapeutics to get $70M in milestone payments from Blackstone Life Sciences | N/A | |
| 2022-12-08 20:05 EST | News | Autolus Therapeutics stock tumbles ~20% after hours as co files for stock offering | N/A | |
| 2022-11-16 06:24 EST | News | Autolus Therapeutics: Near-Term Catalyst Plus Several Bio Deals Could Shift Momentum | N/A | |
| 2022-11-05 06:49 EST | News | Autolus Therapeutics plc 2022 Q3 - Results - Earnings Call Presentation | N/A | |
| 2022-11-05 06:49 EST | News | Autolus Therapeutics plc (AUTL) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-03 21:24 EST | News | Autolus Therapeutics GAAP EPS of -$0.47 in-line, revenue of $2.37M beats by $2.23M | N/A | |
| 2022-10-12 15:17 EST | News | Autolus stock rises as Moderna uses option to license targeting technology for mRNA therapy | N/A | |
| 2022-10-04 11:35 EST | News | Autolus stock rises on Bristol Myers contract for use of safety switch with cell therapies | N/A | |
| 2022-08-17 12:30 EST | News | Autolus Therapeutics: Overlooked CAR-T Player With Key Catalysts Approaching | N/A | |
| 2022-08-08 16:19 EST | News | Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-04 22:04 EST | News | Autolus Therapeutics GAAP EPS of -$0.46 misses by $0.13 | N/A | |
| 2022-08-03 15:56 EST | News | Autolus Therapeutics Q2 2022 Earnings Preview | N/A | |
| 2022-06-18 01:03 EST | News | Autolus Therapeutics (AUTL) Investor Presentation - Slideshow | N/A | |
| 2022-05-10 00:19 EST | News | Autolus Therapeutics plc 2022 Q1 - Results - Earnings Call Presentation | N/A | |
| 2022-05-08 08:57 EST | News | Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-05 18:49 EST | News | Autolus Therapeutics GAAP EPS of -$0.41 beats by $0.07, revenue of $0.17M in-line | N/A | |
| 2022-05-04 19:58 EST | News | Autolus Therapeutics Q1 2022 Earnings Preview | N/A | |
| 2022-04-25 16:05 EST | News | Autolus stock rises 10% on FDA regenerative medicine status for obe-cel to treat blood cancer subtype | N/A | |
| 2022-04-14 17:48 EST | News | Autolus Therapeutics (AUTL) Presents at the American Association for Cancer Research Annual Meeting 2022 - Slideshow | N/A | |
| 2022-03-11 05:33 EST | News | Autolus Therapeutics plc 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-03-11 05:33 EST | News | Autolus Therapeutics plc (AUTL) CEO Dr. Christian Itin on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-10 10:41 EST | News | Autolus Therapeutics GAAP EPS of -$1.97 misses by $0.08, revenue of $2.33M misses by $4.87M | N/A | |
| 2022-03-09 18:19 EST | News | Autolus Therapeutics Q4 2021 Earnings Preview | N/A | |
| 2022-01-14 18:35 EST | News | Autolus Therapeutics (AUTL) Developing Next Generation Programmed T Cell Therapies (Slideshow) | N/A | |
| 2022-01-10 14:00 EST | News | Autolus Therapeutics announces CFO retirement and succession plan | N/A | |
| 2021-12-16 00:39 EST | News | Autolus Therapeutics (AUTL) Presents At 63rd Annual Meeting of ASH - Slideshow | N/A | |
| 2021-11-09 01:43 EST | News | Autolus Therapeutics surges on securing $250M strategic funding from Blackstone | N/A | |
| 2021-11-04 01:46 EST | News | Autolus Therapeutics EPS beats by $0.04, misses on revenue | N/A | |
| 2021-11-04 01:45 EST | News | Autolus Therapeutics plc (AUTL) CEO Dr. Christian Itin on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-03 05:58 EST | News | Autolus Therapeutics Q3 2021 Earnings Preview | N/A | |
| 2021-10-08 01:20 EST | News | MNTV, AUTL, ALLO and CLLS among after hours movers | N/A | |
| 2021-09-22 17:51 EST | News | Autolus Therapeutics provides update on manufacturing facility in U.K. | N/A | |
| 2021-08-07 12:39 EST | News | Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-06 17:03 EST | News | Autolus Therapeutics plc 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-08-06 17:02 EST | News | Autolus Therapeutics files $300M mixed shelf offering | N/A | |
| 2021-08-05 19:58 EST | News | Autolus Therapeutics EPS beats by $0.04, beats on revenue | N/A | |
| 2021-08-03 05:38 EST | News | Moderna gains access to Autolus' binder technology for mRNA immuno-oncology targets | N/A | |
| 2021-07-22 16:22 EST | News | Autolus Therapeutics' obe-cel shows high clinical activity in blood cancers, shares rise 5% | N/A | |
| 2021-07-22 16:17 EST | News | Autolus: Developing Better CAR-T In Refractory ALL | N/A | |
About Autolus Therapeutics plc (AUTL):
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.
General
- Name Autolus Therapeutics plc
- Symbol AUTL
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 376
- Fiscal Year EndSeptember
- IPO Date2018-06-22
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.autolus.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 1470.04
- Price/Book (Most Recent Quarter) 2.32
- Enterprise Value Revenue 1600.67
View More
Financials
- Most Recent Quarter 2020-12-31
- Next Quarter EPS Estimate -$0.78
- Operating Margin -6571%
- Return on Assets -22%
- Return on Equity -30%
- Revenue 1.08 million
- Earnings Per Share -$1.40
- Revenue Per Share $0.03
- Gross Profit -133173000
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 483.68 million
- EBITDA -68942608
- Analyst Target Price $15.78
- Book Value Per Share $5.91
View More
Share Statistics
- Shares Outstanding 70.51 million
- Shares Float 33.9 million
- % Held by Insiders 3186%
- % Held by Institutions 25.44%
- Shares Short 3.51 million
- Shares Short Prior Month 1.71 million
- Short Ratio 2.67
- Short % of Shares Outstanding 5%
View More
Technicals
- Beta 1.75
- 52 Week High $17.19
- 52 Week Low $4
- 50 Day Moving Average 7.05
- 200 Day Moving Average 9.94
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Autolus Therapeutics plc (AUTL) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Autolus Therapeutics plc (AUTL) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-04 | $N/A | -$0.83 | -$0.77 | -8.03% |
| 2020-09-30 | 2020-11-05 | $N/A | -$0.72 | -$0.71 | -1.84% |
| 2020-06-30 | 2020-08-06 | $N/A | -$0.62 | -$0.70 | 11.29% |
| 2020-03-31 | 2020-05-07 | $N/A | -$0.60 | -$0.75 | 19.57% |
| 2019-12-31 | 2020-03-03 | $309000 | -$0.84 | -$0.74 | -14.27% |
| 2019-09-30 | 2019-11-07 | $297000 | -$0.61 | -$0.83 | 26.73% |
| 2019-06-30 | 2019-08-08 | $338000 | -$0.65 | -$0.66 | 0.76% |
| 2019-03-31 | 2019-05-14 | $1.96 million | -$0.69 | -$0.56 | -22.49% |
| 2018-12-31 | 2019-02-25 | $296000 | -$0.52 | -$0.66 | 21.21% |
Autolus Therapeutics plc (AUTL) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Autolus Therapeutics plc (AUTL) Chart:
Autolus Therapeutics plc (AUTL) News:
Below you will find a list of latest news for Autolus Therapeutics plc (AUTL) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Autolus Therapeutics plc (AUTL) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-20 | 2.5 | 1.3 | CALL | 0 | 403 | 401.78 | TRUE | 0 | 0 |
| 2024-12-20 | 5 | 0.45 | CALL | 4 | 473 | 125.55 | FALSE | 0.15 | 0.5 |
| 2024-12-20 | 7.5 | 0.15 | CALL | 0 | 492 | 0 | FALSE | 0 | 0 |
| 2024-12-20 | 10 | 0.01 | CALL | 0 | 15 | 0 | FALSE | 0 | 0 |
| 2024-12-20 | 2.5 | 0.3 | PUT | 0 | 46 | 126.19 | FALSE | 0 | 0 |
| 2024-12-20 | 5 | 1.81 | PUT | 0 | 29 | 112.89 | TRUE | 0 | 0 |
| 2024-12-20 | 7.5 | 4 | PUT | 0 | 6 | 0 | TRUE | 0 | 0 |
| 2024-12-20 | 10 | 0 | PUT | 0 | 0 | 141.4 | TRUE | 0 | 0 |
| 2025-03-21 | 2.5 | 1.5 | CALL | 0 | 73 | 304.34 | TRUE | 0 | 0 |
| 2025-03-21 | 5 | 0.6 | CALL | 0 | 101 | 105.29 | FALSE | 0 | 0 |
| 2025-03-21 | 7.5 | 0.2 | CALL | 0 | 115 | 104.91 | FALSE | 0 | 0 |
| 2025-03-21 | 2.5 | 0.5 | PUT | 0 | 22 | 0 | FALSE | 0 | 0 |
| 2025-03-21 | 5 | 2.12 | PUT | 0 | 108 | 0 | TRUE | 0 | 0 |
| 2025-03-21 | 7.5 | 3.6 | PUT | 0 | 3 | 98.83 | TRUE | 0 | 0 |
| 2025-12-19 | 2.5 | 0 | CALL | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-12-19 | 5 | 1 | CALL | 0 | 8 | 0 | FALSE | 0 | 0 |
| 2025-12-19 | 7.5 | 0.45 | CALL | 0 | 20 | 0 | FALSE | 0 | 0 |
| 2025-12-19 | 2.5 | 0.57 | PUT | 0 | 4 | 0 | FALSE | 0 | 0 |
| 2025-12-19 | 5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-12-19 | 7.5 | 0 | PUT | 0 | 0 | 132.56 | TRUE | 0 | 0 |
Latest AUTL Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:45 PM EST | 100 | $2.265 |
| Jun 13, 2022 7:46 PM EST | 100 | $2.25 |
| Jun 13, 2022 7:46 PM EST | 100 | $2.245 |
| Jun 13, 2022 7:47 PM EST | 100 | $2.24 |
| Jun 13, 2022 7:47 PM EST | 38 | $2.245 |
Autolus Therapeutics plc (AUTL) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-30 | 20-F/A | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1730463/000119312520184031/0001193125-20-184031-index.htm |
| 2019-07-22 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1730463/000000000019011382/0000000000-19-011382-index.htm |
| 2020-06-18 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1730463/000000000020005460/0000000000-20-005460-index.htm |
| 2020-07-09 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1730463/000000000020006207/0000000000-20-006207-index.htm |
| 2019-02-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1730463/000119312519038198/0001193125-19-038198-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1730463/000119312519039614/0001193125-19-039614-index.htm |
| 2019-02-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1730463/000119312519049964/0001193125-19-049964-index.htm |
| 2019-03-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1730463/000119312519076928/0001193125-19-076928-index.htm |
| 2019-03-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1730463/000119312519088447/0001193125-19-088447-index.htm |
| 2019-04-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1730463/000119312519095146/0001193125-19-095146-index.htm |
| 2019-04-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1730463/000119312519099275/0001193125-19-099275-index.htm |
| 2019-04-08 | F-1 | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1730463/000119312519100758/0001193125-19-100758-index.htm |
| 2019-04-08 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1730463/000119312519100812/0001193125-19-100812-index.htm |
| 2019-04-08 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1730463/000119312519100816/0001193125-19-100816-index.htm |
| 2019-04-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1730463/000119312519100854/0001193125-19-100854-index.htm |
| 2019-04-10 | F-1MEF | Registration statement to add securities to prior Form F-1 registration [Rule 462(b)] | https://www.sec.gov/Archives/edgar/data/1730463/000119312519103095/0001193125-19-103095-index.htm |
| 2019-04-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1730463/000119312519103379/0001193125-19-103379-index.htm |
| 2019-04-11 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1730463/000119312519103862/0001193125-19-103862-index.htm |
| 2019-07-17 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1730463/000119312519195733/0001193125-19-195733-index.htm |
| 2019-07-22 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1730463/000119312519198985/0001193125-19-198985-index.htm |
| 2019-07-24 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1730463/000119312519201243/0001193125-19-201243-index.htm |
| 2020-01-22 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1730463/000119312520012120/0001193125-20-012120-index.htm |
| 2020-01-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1730463/000119312520014188/0001193125-20-014188-index.htm |
| 2020-01-24 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1730463/000119312520014199/0001193125-20-014199-index.htm |
| 2020-01-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1730463/000119312520021437/0001193125-20-021437-index.htm |
| 2020-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1730463/000119312520031373/0001193125-20-031373-index.htm |
| 2020-05-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1730463/000119312520151568/0001193125-20-151568-index.htm |
| 2020-06-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1730463/000119312520175566/0001193125-20-175566-index.htm |
| 2020-06-30 | 20-F/A | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1730463/000119312520184031/0001193125-20-184031-index.htm |
| 2020-06-30 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1730463/000119312520184048/0001193125-20-184048-index.htm |
| 2020-08-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1730463/000119312520231538/0001193125-20-231538-index.htm |
| 2020-09-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1730463/000119312520248586/0001193125-20-248586-index.htm |
| 2020-09-18 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1730463/000119312520248640/0001193125-20-248640-index.htm |
| 2019-01-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1730463/000121390019000521/0001213900-19-000521-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1730463/000121390019002514/0001213900-19-002514-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1730463/000121390019002532/0001213900-19-002532-index.htm |
| 2019-08-08 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1730463/000121390019014928/0001213900-19-014928-index.htm |
| 2019-09-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1730463/000121390019017502/0001213900-19-017502-index.htm |
| 2019-09-16 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1730463/000121390019018073/0001213900-19-018073-index.htm |
| 2019-09-20 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1730463/000121390019018491/0001213900-19-018491-index.htm |
| 2019-10-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1730463/000121390019020030/0001213900-19-020030-index.htm |
| 2019-10-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1730463/000121390019020032/0001213900-19-020032-index.htm |
| 2020-01-24 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1730463/000121390020001740/0001213900-20-001740-index.htm |
| 2020-04-22 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1730463/000121390020009830/0001213900-20-009830-index.htm |
| 2020-06-15 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1730463/000121390020015014/0001213900-20-015014-index.htm |
| 2020-07-06 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1730463/000121390020016740/0001213900-20-016740-index.htm |
| 2020-07-20 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1730463/000121390020017961/0001213900-20-017961-index.htm |
| 2020-08-03 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1730463/000121390020019894/0001213900-20-019894-index.htm |
| 2020-08-13 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1730463/000121390020021871/0001213900-20-021871-index.htm |
| 2020-03-03 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1730463/000162828020002797/0001628280-20-002797-index.htm |
| 2019-02-25 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1730463/000173046319000004/0001730463-19-000004-index.htm |
| 2019-05-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1730463/000173046319000008/0001730463-19-000008-index.htm |
| 2019-08-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1730463/000173046319000011/0001730463-19-000011-index.htm |
| 2019-11-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1730463/000173046319000013/0001730463-19-000013-index.htm |
| 2020-05-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1730463/000173046320000003/0001730463-20-000003-index.htm |
| 2020-08-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1730463/000173046320000008/0001730463-20-000008-index.htm |
| 2020-11-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1730463/000173046320000011/0001730463-20-000011-index.htm |
| 2019-04-10 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1730463/999999999519000665/9999999995-19-000665-index.htm |
| 2019-07-24 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1730463/999999999519001680/9999999995-19-001680-index.htm |